Market Summary
USD52.93-0.14
Market Closed-0.26%
GMED Stock Price
GMED RSI Chart
GMED Valuation
GMED Price/Sales (Trailing)
GMED Profitability
GMED Fundamentals
GMED Revenue
GMED Earnings
Price Action
52 Week Range
50.9280.04
(Low)(High)
Last 7 days
-5.7%
Last 30 days
-8.2%
Last 90 days
-9.9%
Trailing 12 Months
-20.0%
GMED Financial Health
GMED Investor Care
Peers (Alternatives to Globus Medical)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 110.8B | 19.0B | -8.78% | 16.43% | 46.98 | 6.01 | 8.73% | 30.37% |
ISRG | 107.5B | 6.4B | 4.05% | 37.44% | 81.96 | 16.72 | 8.89% | -20.19% |
BSX | 74.1B | 13.0B | -0.08% | 27.20% | 106.12 | 5.84 | 7.26% | -32.95% |
BDX | 71.3B | 18.8B | -6.73% | -3.13% | 44.09 | 3.79 | -1.96% | -15.83% |
EW | 49.7B | 5.5B | -6.18% | -16.80% | 33.38 | 9.03 | 2.68% | -3.23% |
| MID-CAP | ||||||||
SWAV | 7.2T | 557.2M | -1.64% | 66.40% | 82.2K | 16.8K | 86.42% | 730.06% |
PEN | 11.7B | 884.6M | 7.85% | 115.97% | 1.8K | 13.2 | 13.08% | 200.12% |
GMED | 5.9B | 1.1B | -8.20% | -19.98% | 34.14 | 5.75 | 11.20% | 53.04% |
IRTC | 3.6B | 430.0M | -11.89% | -12.63% | -34.73 | 8.45 | 26.13% | 15.73% |
TNDM | 1.7B | 794.7M | -29.15% | -60.56% | -8.43 | 2.16 | 7.73% | -3556.34% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 389.0M | -3.76% | 82.19% | -10.63 | 4.18 | 44.08% | 6.96% |
SILK | 1.2B | 150.7M | -30.80% | 0.49% | -21.65 | 7.87 | 40.31% | 1.80% |
AVNS | 1.1B | 814.3M | -20.14% | -16.22% | 24.47 | 1.34 | 6.96% | 121.89% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
Financials for Globus Medical
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | 4.5% | 1,069 | 1,023 | 998 | 974 | 961 |
| Gross Profit | 4.5% | 794 | 759 | 743 | 726 | 718 |
| Operating Expenses | 4.6% | 556 | 531 | 551 | 540 | 554 |
| S&GA Expenses | 5.0% | 454 | 432 | 421 | 410 | 411 |
| R&D Expenses | 5.0% | 77.00 | 73.00 | 105 | 102 | 100 |
| EBITDA | 16.4% | 326 | 280 | 270 | 251 | - |
| EBITDA Margin | 13.6% | 0.32* | 0.28* | 0.28* | 0.26* | - |
| Earnings Before Taxes | 5.9% | 257 | 243 | 201 | 194 | 172 |
| EBT Margin | 18.2% | 0.24* | 0.20* | 0.20* | 0.18* | - |
| Interest Expenses | 31.1% | 14.00 | 11.00 | 9.00 | 9.00 | - |
| Net Income | 12.4% | 194 | 172 | 126 | 131 | 127 |
| Net Income Margin | 33.4% | 0.17* | 0.13* | 0.16* | 0.14* | - |
| Free Cahsflow | -11.5% | 104 | 118 | 157 | 194 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | 3.5% | 2,150 | 2,076 | 1,977 | 1,915 | 1,999 |
| Current Assets | 8.9% | 1,070 | 983 | 920 | 891 | 917 |
| Cash Equivalents | 44.7% | 218 | 150 | 134 | 151 | 230 |
| Inventory | 7.4% | 321 | 299 | 282 | 266 | 254 |
| Net PPE | 0.6% | 245 | 244 | 236 | 239 | 228 |
| Goodwill | 0.6% | 199 | 197 | 182 | 5.00 | 179 |
| Liabilities | 2.2% | 235 | 230 | 212 | 216 | 213 |
| Current Liabilities | 5.2% | 168 | 159 | 145 | 146 | 141 |
| Shareholder's Equity | 3.7% | 1,915 | 1,846 | 1,764 | 1,699 | 1,785 |
| Retained Earnings | 4.0% | 1,289 | 1,240 | 1,190 | 1,142 | 1,232 |
| Additional Paid-In Capital | 2.2% | 645 | 631 | 606 | 582 | 570 |
| Accumulated Depreciation | 3.2% | 354 | 343 | 333 | 322 | 314 |
| Shares Outstanding | -1.0% | 100 | 101 | 102 | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | 4.8% | 187 | 178 | 191 | 235 | 257 |
| Share Based Compensation | 2.4% | 34.00 | 33.00 | 32.00 | 31.00 | 31.00 |
| Cashflow From Investing | 22.5% | -85.48 | -110 | -293 | -237 | -264 |
| Cashflow From Financing | -2.8% | -113 | -109 | -124 | -115 | 53.00 |
| Buy Backs | -50.0% | 144 | 289 | 578 | - | - |
Risks for GMED
What is the probability of a big loss on GMED?
75%
Probability that Globus Medical stock will be more than 20% underwater in next one year
37.3%
Probability that Globus Medical stock will be more than 30% underwater in next one year.
0%
Probability that Globus Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does GMED drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Globus Medical was unfortunately bought at previous high price.
Drawdowns
Returns for GMED
Cumulative Returns on GMED
13.5%
10-Year Cumulative Returns
12.0%
7-Year Cumulative Returns
-0.6%
5-Year Cumulative Returns
-1.0%
3-Year Cumulative Returns
What are the long-term rolling returns for GMED?
FIve years rolling returns for Globus Medical.
Annualized Returns
Which funds bought or sold GMED recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | reduced | -17.03 | -162,077 | 279,235 | -% |
2023-05-25 | WATER ISLAND CAPITAL LLC | new | - | 6,247,000 | 6,247,000 | 0.51% |
2023-05-25 | Brandywine Global Investment Management, LLC | added | 105 | 3,906,790 | 10,787,300 | 0.04% |
2023-05-25 | Legato Capital Management LLC | unchanged | - | -285,518 | 917,285 | 0.17% |
2023-05-24 | Mint Tower Capital Management B.V. | new | - | 255,000 | 255,000 | 0.03% |
2023-05-23 | Front Row Advisors LLC | unchanged | - | -2,000 | 5,000 | -% |
2023-05-23 | Seaport Global Advisors, LLC | reduced | -52.32 | -361,434 | 206,509 | 0.65% |
2023-05-23 | Capital Impact Advisors, LLC | reduced | -62.47 | -948,095 | 380,224 | 0.47% |
2023-05-23 | Brookfield Corp /ON/ | new | - | 981,515 | 981,515 | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 10.48 | -1,323,060 | 7,082,940 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Globus Medical News
Schedule 13G FIlings of Globus Medical
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | paul david c | 21.57% | 21,389,400 | SC 13G/A | |
| Feb 14, 2023 | kayne anderson rudnick investment management llc | 7.99% | 6,184,472 | SC 13G | |
| Feb 10, 2023 | janus henderson group plc | 5.6% | 5,633,954 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.47% | 7,332,112 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.7% | 7,474,453 | SC 13G/A | |
| Feb 09, 2022 | paul david c | 21.21% | 21,296,692 | SC 13G/A | |
| Feb 07, 2022 | blackrock inc. | 7.2% | 7,298,945 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 4.07% | 3,216,224 | SC 13G/A | |
| Feb 16, 2021 | paul david c | 21.52% | 21,196,692 | SC 13G/A | |
| Feb 11, 2021 | janus henderson group plc | 6.5% | 6,441,759 | SC 13G/A |
GMED Fair Value
Recent SEC filings of Globus Medical
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 17, 2023 | 4 | Insider Trading | |
| May 16, 2023 | 144 | Notice of Insider Sale Intent | |
| May 04, 2023 | 10-Q | Quarterly Report | |
| May 04, 2023 | 8-K | Current Report | |
| May 03, 2023 | 8-K | Current Report | |
| May 02, 2023 | DEFA14A | DEFA14A | |
| Apr 28, 2023 | 425 | Prospectus Filed | |
| Apr 28, 2023 | 8-K | Current Report | |
| Apr 28, 2023 | DEF 14A | DEF 14A | |
| Apr 28, 2023 | DEFA14A | DEFA14A |
Latest Insider Trading transactions for GMED
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-15 | Lemaitre Dan | acquired | 1,104,780 | 25.4265 | 43,450 | - |
2023-05-15 | Lemaitre Dan | sold | -2,475,980 | 56.9845 | -43,450 | - |
2023-02-09 | Lemaitre Dan | acquired | 132,922 | 23.95 | 5,550 | - |
2023-02-02 | Pfeil Keith W | sold | -2,262,430 | 77.568 | -29,167 | svp, chief financial officer |
2023-02-02 | Pfeil Keith W | acquired | 1,502,440 | 51.5117 | 29,167 | svp, chief financial officer |
2023-01-27 | RHOADS ANN D | acquired | 94,425 | 12.59 | 7,500 | - |
2023-01-27 | Lemaitre Dan | acquired | 66,097 | 12.59 | 5,250 | - |
2022-12-01 | Huller Kelly | acquired | 94,425 | 12.59 | 7,500 | svp, gc, corporate secretary |
2022-12-01 | Huller Kelly | sold | -562,501 | 75.0001 | -7,500 | svp, gc, corporate secretary |
2022-04-19 | Davidar David D | sold | -2,458,070 | 78.034 | -31,500 | - |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
GMED Income Statement
2023-03-31CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME [Abstract] | ||
| Net sales | $ 276,688 | $ 230,549 |
| Cost of goods sold | 70,825 | 59,167 |
| Gross profit | 205,863 | 171,382 |
| Operating expenses: | ||
| Research and development | 21,082 | 17,412 |
| Selling, general and administrative | 122,416 | 100,748 |
| Provision for litigation | 2,341 | |
| Amortization of intangibles | 4,601 | 4,512 |
| Acquisition related costs | 1,361 | (76) |
| Total operating expenses | 149,460 | 124,937 |
| Operating income/(loss) | 56,403 | 46,445 |
| Other income/(expense), net | ||
| Interest income/(expense), net | 6,497 | 2,543 |
| Foreign currency transaction gain/(loss) | 212 | (391) |
| Other income/(expense) | 77 | 301 |
| Total other income/(expense), net | 6,786 | 2,453 |
| Income/(loss) before income taxes | 63,189 | 48,898 |
| Income tax provision | 14,060 | 10,814 |
| Net income/(loss) | 49,129 | 38,084 |
| Other comprehensive income/(loss), net of tax: | ||
| Unrealized gain/(loss) on marketable securities | 4,298 | (8,828) |
| Foreign currency translation gain/(loss) | 910 | (1,567) |
| Total other comprehensive income/(loss), net of tax | 5,208 | (10,395) |
| Comprehensive income/(loss) | $ 54,337 | $ 27,689 |
| Earnings per share: | ||
| Basic | $ 0.49 | $ 0.37 |
| Diluted | $ 0.48 | $ 0.37 |
| Weighted average shares outstanding: | ||
| Basic | 100,279 | 101,600 |
| Diluted | 102,196 | 104,077 |
GMED Balance Sheet
2023-03-31CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 217,685 | $ 150,466 |
| Short-term marketable securities | 286,685 | 295,592 |
| Accounts receivable, net of allowances of $5,514 and $4,724, respectively | 222,783 | 213,247 |
| Inventories | 321,033 | 298,981 |
| Prepaid expenses and other current assets | 19,201 | 20,997 |
| Income taxes receivable | 3,042 | 4,061 |
| Total current assets | 1,070,429 | 983,344 |
| Property and equipment, net of accumulated depreciation of $353,868 and $343,036, respectively | 245,098 | 243,729 |
| Long-term marketable securities | 480,025 | 495,852 |
| Intangible assets, net | 59,194 | 63,574 |
| Goodwill | 198,710 | 197,471 |
| Other assets | 44,985 | 43,311 |
| Deferred income taxes | 51,179 | 48,845 |
| Total assets | 2,149,620 | 2,076,126 |
| Current liabilities: | ||
| Accounts payable | 39,835 | 36,101 |
| Accrued expenses | 83,998 | 94,705 |
| Income taxes payable | 16,389 | 990 |
| Business acquisition liabilities | 13,784 | 13,308 |
| Deferred revenue | 13,541 | 14,100 |
| Total current liabilities | 167,547 | 159,204 |
| Business acquisition liabilities, net of current portion | 52,486 | 54,950 |
| Deferred income taxes | 1,369 | 1,779 |
| Other liabilities | 13,398 | 13,820 |
| Total liabilities | 234,800 | 229,753 |
| Commitments and contingencies (Note 15) | ||
| Equity: | ||
| Additional paid-in capital | 645,062 | 630,952 |
| Accumulated other comprehensive income/(loss) | (19,422) | (24,630) |
| Retained earnings | 1,289,080 | 1,239,951 |
| Total equity | 1,914,820 | 1,846,373 |
| Total liabilities and equity | 2,149,620 | 2,076,126 |
| Common Class A [Member] | ||
| Equity: | ||
| Common stock | 78 | 78 |
| Common Class B [Member] | ||
| Equity: | ||
| Common stock | $ 22 | $ 22 |